Zobrazeno 1 - 10
of 177
pro vyhledávání: ''
Autor:
James C. Padussis, Jane L. Meza, Quan P. Ly, Michael A. Hollingsworth, Chandrakanth Are, Audrey J. Lazenby, Vivek Verma, Chi Lin, Madi Madiyalakan, Christopher F. Nicodemus, Lyudmyla Berim, Jean L. Grem, James K. Schwarz
Publikováno v:
Am J Clin Oncol
Objective Cancer antigen (CA)-125 influences progression, metastasis, and outcomes in pancreatic cancer. This phase I/II trial (NCT01959672) evaluated the safety, efficacy, and immunologic correlates of chemoimmunotherapy (CIT) with oregovomab (anti-
Autor:
Panteleimon Kountourakis, Athanasios Petrou, Dimitrios Schizas, Nikolaos Dimitrokallis, Dimitrios Oikonomou, Michalis V. Karamouzis, Georgios Astras, Demetris Papamichael, Spyridon Davakis, Alexandros Papalampros, Dimitrios Moris, Evangelos Felekouras
Publikováno v:
American journal of clinical oncology. 44(7)
Objectives Locally advanced pancreatic cancer (LAPC) is found in about 40% of patients with pancreatic cancer. Irreversible electroporation (IRE) is a nonthermal ablative technique that provides an alternative in patients with LAPC and can be safely
Publikováno v:
American Journal of Clinical Oncology. 42:154-159
Patients with unresectable cT4b esophageal cancer (EC) are rare and largely excluded from prospective trials. As a result, current treatment recommendations are based on limited evidence. This study sought to evaluate national practice patterns and o
Publikováno v:
American Journal of Clinical Oncology. 41:943-948
The impact of concomitant urologic procedures (UPs) on perioperative and long-term outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is uncertain.In total, 935 consecutive CRS/HIPEC procedures were perform
Publikováno v:
American journal of clinical oncology. 43(4)
OBJECTIVES Natural killer/T-cell lymphoma (NKTCL) is aggressive, and carries a poor prognosis worldwide. This retrospective study aimed to evaluate the clinical efficacy and safety of the LVD regimen (L-asparaginase, vincristine, and dexamethasone) c
Publikováno v:
American journal of clinical oncology. 42(10)
Background Primary systemic therapy in resectable pancreatic cancer is currently under investigation. FOLFIRINOX has been shown to be effective in both the adjuvant and metastatic settings and is increasingly being used on and off study in the neoadj
Autor:
Carlos Fernandez-del Castillo, Jennifer Y. Wo, Theodore S. Hong, Keith D. Lillemoe, Jill N. Allen, Cristina R. Ferrone, Florence K. Keane, Lawrence S. Blaszkowsky, David P. Ryan, Eunice L. Kwak, Jeffrey W. Clark
Publikováno v:
American Journal of Clinical Oncology. 41:607-612
Improved outcomes with FOLFIRINOX or gemcitabine with nab-paclitaxel in the treatment of metastatic pancreatic adenocarcinoma (PDAC) have prompted incorporation of these regimens into neoadjuvant treatment of locally advanced unresectable PDAC. Where
Autor:
Jolanda M. van Dieren, Rosa T. van der Kaaij, Francine E.M. Voncken, Karolina Sikorska, Petur Snaebjornsson, Erik van Werkhoven, Cecile Grootscholten, Johanna W. van Sandick, Berthe M.P. Aleman
Publikováno v:
American journal of clinical oncology, 41(9), 919-926. Lippincott Williams and Wilkins
Objectives The objective of this study is to compare long-term outcomes between younger and older (70 y and above) esophageal cancer patients treated with curative intent. Materials and methods Overall survival (OS), disease-free survival (DFS), and
Publikováno v:
American Journal of Clinical Oncology. 39:575-580
OBJECTIVES The effect of ethnicity on nasopharyngeal cancer (NPC) outcomes is unclear. This retrospective analysis examines survival and the impact of concurrent chemoradiation (chemoRT) among Asian and non-Asian patients. METHODS Subjects included 3
Autor:
Jolanda M. van Dieren, Cecile Grootscholten, Berthe M.P. Aleman, Johanna W. van Sandick, Petur Snaebjornsson, Rosa T. van der Kaaij, Catharina M Korse, Francine E.M. Voncken
Publikováno v:
American journal of clinical oncology. 42(4)
INTRODUCTION Chemoradiotherapy and surgery are the basis of the potentially curative treatment for esophageal cancer. Approximately 1 in 5 patients, however, do not benefit from this intensive treatment due to early treatment failure. The aim of this